Antibody Drug Conjugates in Oncology Market Report: 2027-2031 Forecast, Strategic Opportunities by Indication, Payload, Target Antigen, Linker Chemistry, Structural Format and Country - Strategic Analysis of 52 Companies

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis

2.1 Forecast Approach
2.2 Data Sources
2.3 Scope & Definitions
2.4 Limitations

3.1 Mechanism of Action & Structural Components
3.2 Evolution from First- to Fourth-Generation ADCs
3.3 Adjacent Modalities

4.1 Global Market Overview by Country
4.2 Global Market by Indication - Overview
4.3 Global Market by Payload - Overview
4.4 Global Market by Antigen - Overview
4.5 Global Market by Linker - Overview
4.6 Global Market by Format - Overview

5.1 Full Approved ADC Registry
5.2 Technology Benchmarking
5.3 Commercial Benchmarking - Top-Selling Approved ADCs
5.4 Regulatory Risk Case Studies

6.1 Pipeline Overview
6.2 Pipeline Distribution by Phase
6.3 Target Antigen Crowding
6.4 Sponsor Geographic Distribution

7.1 Conjugation Chemistry
7.2 Linker Platforms
7.3 Payload Classes
7.4 Next-Generation Structural Formats
7.5 Platform Technology Licensors

8.1 ADC + Checkpoint Inhibitor Combinations
8.2 ADC + Targeted Therapy Combinations
8.3 Commercial and Biological Rationale

9.1 FDA Approval Pathways
9.2 EMA & NMPA Pathways
9.3 HTA & Reimbursement Dynamics
9.4 Patent & Biosimilar Overview

10.1 Expiry Timeline
10.2 Biosimilar Pipeline
10.3 Anticipated Price Erosion

11.1 Key Originators
11.2 Why Global Pharma Is Buying In

12.1 Recent Developments - Importance and How to Use This Section
12.2 Enhertu approved for HER2-positive early breast cancer
12.3 Trodelvy wins first-line approval in metastatic triple-negative breast cancer
12.4 Padcev plus Keytruda approved for muscle-invasive bladder cancer
12.5 China approves iza-bren, the world's first bispecific ADC
12.6 Gilead to acquire Tubulis for up to $5 billion
12.7 Merck and Kelun's sac-TMT beats Keytruda in first-line lung cancer
12.8 Blenrep returns to the U.S. market
12.9 FDA approves AbbVie's Decnupaz in a rare blood cancer
12.10 BMS's iza-bren hits both survival endpoints in Phase 3 breast cancer trial
12.11 Lilly acquires CrossBridge Bio for dual-payload ADC technology

13.1 Bioconjugation Capacity Landscape
13.2 CDMO Competitive Positioning
13.3 In-House vs. Outsourced Manufacturing Trends
13.4 Capacity Bottlenecks and Outlook

14.1 Market Structure: Three Different Rankings
14.2 Big Pharma / Large-Cap Portfolios
14.3 Emerging China-Originated Players
14.4 Outlook

15.1 SWOT Analysis
15.2 Porter's Five Forces
15.3 Key Investment Risks

16.1 White-Space Opportunities
16.2 Partnering Strategy Guidance

17.1 Breast cancer (HER2+)
17.2 Breast cancer (HER2-low)
17.3 Triple-negative breast cancer
17.4 Non-small cell lung cancer
17.5 Bladder cancer
17.6 Hematologic malignancies (blood/lymph)
17.7 Gynecologic cancers
17.8 Gastric / GEJ cancer
17.9 Other indications

18.1 Auristatins (MMAE/MMAF)
18.2 Maytansinoids (DM1/DM4)
18.3 Topoisomerase-I inhibitors
18.4 PBD dimers
18.5 Tubulysins
18.6 Other payloads

19.1 HER2
19.2 TROP2
19.3 CD30
19.4 CD33
19.5 CD79b
19.6 Nectin-4
19.7 FOLR1 (FRa)
19.8 Other antigens

20.1 Cleavable - protease-sensitive
20.2 Cleavable - pH-sensitive
20.3 Cleavable - glutathione-sensitive
20.4 Non-cleavable
20.5 Other linkers

21.1 Conventional ADC
21.2 Dual-payload ADC
21.3 Bispecific-antibody ADC
21.4 Antibody-oligonucleotide conjugate (AOC)

22.1 3SBio
22.2 AbbVie
22.3 Abzena
22.4 ADC Therapeutics
22.5 Astellas Pharma
22.6 AstraZeneca
22.7 Axplora (Novasep)
22.8 Biokin Pharma
22.9 Boehringer Ingelheim (via NBE Therapeutics)
22.10 Bristol Myers Squibb
22.11 Byondis
22.12 Catalent (Novo Holdings)
22.13 CordenPharma
22.14 CSPC Pharmaceutical Group
22.15 CytomX Therapeutics
22.16 Daiichi Sankyo
22.17 DualityBio
22.18 Formosa Pharmaceuticals
22.19 Fosun Pharma
22.20 Genmab
22.21 Gilead Sciences
22.22 GSK
22.23 Hansoh Pharma
22.24 Heidelberg Pharma
22.25 Iksuda Therapeutics
22.26 ImmunoGen (historical)
22.27 Immunomedics (historical)
22.28 Innate Pharma
22.29 Innovent Biologics
22.30 Jiangsu Hengrui Pharmaceuticals
22.31 Johnson & Johnson (Ambrx)
22.32 Kelun-Biotech
22.33 LegoChem Biosciences
22.34 Lepu Biopharma
22.35 Lonza
22.36 MacroGenics
22.37 Merck & Co.
22.38 Mersana Therapeutics
22.39 Pfizer
22.40 Piramal Pharma Solutions
22.41 Rakuten Medical
22.42 RemeGen
22.43 Roche/Genentech
22.44 Samsung Biologics
22.45 Seagen (historical)
22.46 Sterling Pharma Solutions
22.47 Sutro Biopharma
22.48 Synaffix
22.49 Takeda
22.50 WuXi XDC
22.51 Zydus Cadila
22.52 Zymeworks

23.1 Abbreviations
23.2 Report Limitations Restated

Table 1 Global Market by Country
Table 2 Global Market by Indication
Table 3 Global Market by Payload
Table 4 Global Market by Antigen
Table 5 Global Market by Linker
Table 6 Global Market by Format
Table 7 Breast cancer (HER2+) by Country
Table 8 Breast cancer (HER2-low) by Country
Table 9 Triple-negative breast cancer by Country
Table 10 Non-small cell lung cancer by Country
Table 11 Bladder cancer by Country
Table 12 Hematologic malignancies (blood/lymph) by Country
Table 13 Gynecologic cancers by Country
Table 14 Gastric / GEJ cancer by Country
Table 15 Other indications by Country
Table 16 Auristatins (MMAE/MMAF) by Country
Table 17 Maytansinoids (DM1/DM4) by Country
Table 18 Topoisomerase-I inhibitors by Country
Table 19 PBD dimers by Country
Table 20 Tubulysins by Country
Table 21 Other payloads by Country
Table 22 HER2 by Country
Table 23 TROP2 by Country
Table 24 CD30 by Country
Table 25 CD33 by Country
Table 26 CD79b by Country
Table 27 Nectin-4 by Country
Table 28 FOLR1 (FRa) by Country
Table 29 Other antigens by Country
Table 30 Cleavable - protease-sensitive by Country
Table 31 Cleavable - pH-sensitive by Country
Table 32 Cleavable - glutathione-sensitive by Country
Table 33 Non-cleavable by Country
Table 34 Other linkers by Country
Table 35 Conventional ADC by Country
Table 36 Dual-payload ADC by Country
Table 37 Bispecific-antibody ADC by Country
Table 38 Antibody-oligonucleotide conjugate (AOC) by Country

Figure 1 Global ADC Market by Indication, 2026-2031
Figure 1 Key Graphic - Where the next $16.9 billion comes from
Figure 2 Global Market Pareto Chart
Figure 3 Global Market by Indication - Base vs. Final
Figure 4 Global Market by Indication Base Year
Figure 5 Global Market by Indication End Year
Figure 6 Indication Share by Year
Figure 7 Indication Segments Growth
Figure 8 Global Market by Payload - Base vs. Final
Figure 9 Global Market by Payload Base Year
Figure 10 Global Market by Payload End Year
Figure 11 Payload Share by Year
Figure 12 Payload Segments Growth
Figure 13 Global Market by Antigen - Base vs. Final
Figure 14 Global Market by Antigen Base Year
Figure 15 Global Market by Antigen End Year
Figure 16 Antigen Share by Year
Figure 17 Antigen Segments Growth
Figure 18 Global Market by Linker - Base vs. Final
Figure 19 Global Market by Linker Base Year
Figure 20 Global Market by Linker End Year
Figure 21 Linker Share by Year
Figure 22 Linker Segments Growth
Figure 23 Global Market by Format - Base vs. Final
Figure 24 Global Market by Format Base Year
Figure 25 Global Market by Format End Year
Figure 26 Format Share by Year
Figure 27 Format Segments Growth
Figure 28 Breast cancer (HER2+) Growth
Figure 29 Breast cancer (HER2-low) Growth
Figure 30 Triple-negative breast cancer Growth
Figure 31 Non-small cell lung cancer Growth
Figure 32 Bladder cancer Growth
Figure 33 Hematologic malignancies (blood/lymph) Growth
Figure 34 Gynecologic cancers Growth
Figure 35 Gastric / GEJ cancer Growth
Figure 36 Other indications Growth
Figure 37 Auristatins (MMAE/MMAF) Growth
Figure 38 Maytansinoids (DM1/DM4) Growth
Figure 39 Topoisomerase-I inhibitors Growth
Figure 40 PBD dimers Growth
Figure 41 Tubulysins Growth
Figure 42 Other payloads Growth
Figure 43 HER2 Growth
Figure 44 TROP2 Growth
Figure 45 CD30 Growth
Figure 46 CD33 Growth
Figure 47 CD79b Growth
Figure 48 Nectin-4 Growth
Figure 49 FOLR1 (FRa) Growth
Figure 50 Other antigens Growth
Figure 51 Cleavable - protease-sensitive Growth
Figure 52 Cleavable - pH-sensitive Growth
Figure 53 Cleavable - glutathione-sensitive Growth
Figure 54 Non-cleavable Growth
Figure 55 Other linkers Growth
Figure 56 Conventional ADC Growth
Figure 57 Dual-payload ADC Growth
Figure 58 Bispecific-antibody ADC Growth
Figure 59 Antibody-oligonucleotide conjugate (AOC) Growth